ClinicalTrials.gg
Not yet recruitingNCT07477782FMT-SCLERUpdated Mar 17, 2026

Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation

A Phase 2 interventional study of Fecal microbiota transplantation (FMT) and Sham-transplantation (placebo) in Primary Sclerosing Cholangitis (PSC) and Inflammatory Bowel Disease (IBD), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Cholangitis, Sclerosing with a site in France — 4 open to participants now, 6 under way, 2 of them phase 3. Cholangitis, Sclerosing · France.

Planned enrollment
8th of 13
72 · median 81
Started
2026
with 2 others
Phase 2
7 of 17
1 open now
Registered
16th of 17
by date
Lead sponsor
6 of 17
Assistance Publique - Hôpitaux de Paris

Among the 17 studies in Cholangitis, Sclerosing with a site in France, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 2, and was the 16th registered.

Cholangitis, Sclerosing

152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

4 of the 17 studies in Cholangitis, Sclerosing with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Cholangitis, Sclerosing with a site in France, or all of them as a file.
02

Study summary

Primary Sclerosing Cholangitis (PSC) is a rare cholestatic liver disease, commonly associated with inflammatory bowel disease (IBD) The aim of the present trial is to assess the efficacy of fecal microbiota transplantation (FMT) on ALP and bilirubin compared to sham transplantation in addition to ursodeoxycholic acid (UDCA) treatment in PSC patients.

Read the detailed description

Primary Sclerosing Cholangitis (PSC) is a rare cholestatic liver disease, commonly associated with inflammatory bowel disease (IBD) and characterized by progressive obliterative fibrosis of the biliary tree. PSC can lead to cirrhosis, end-stage liver disease, and hepatobiliary and colorectal cancer. Serum levels of alkaline phosphatase (ALP) and bilirubin are markers of cholestasis and have a prognostic value in PSC.

Liver transplantation is the only validated treatment since no medication has been reported to improve survival of PSC patients. However, ursodeoxycholic acid (UDCA), which has shown efficacy to improve liver tests, notably ALP, is approved for treatment of PSC and is prescribed in all PSC patients in France. Several studies have demonstrated that the gut microbiota plays an important role in the pathogenesis and the progression of PSC. First, PSC patients display an intestinal dysbiosis, regardless of IBD status. This dysbiosis is characterized by a decrease in diversity and some changes in the composition of gut microbiota. Second, fecal microbiota transplantation (FMT) from PSC patients into mice aggravate the cholestatic liver disease, suggesting an impact of the gut microbiota on PSC. Third, modulation of gut microbiota by antibiotic therapy can improve liver tests in PSC patients. A recent uncontrolled study, performed in 10 PSC patients, showed that FMT was safe. Moreover, in this study, a single FMT was associated with a reduction of ALP levels in 33% patients. FMT also increased bacterial diversity in all patients, and abundance of engrafted bacteria in patients post-FMT tended to be correlated with decreased ALP levels. Thus, FMT could be a useful therapy in PSC patients. The aim of the present trial is to assess the efficacy of FMT on ALP and bilirubin compared to sham transplantation in addition to UDCA treatment in PSC patients.

03

Conditions studied

  • Primary Sclerosing Cholangitis (PSC)
  • Inflammatory Bowel Disease (IBD)

Keywords

  • Primary Sclerosing Cholangitis
  • inflammatory bowel disease
  • fecal microbiota transplantation
  • ursodeoxycholic acid
  • alkaline phosphatase
  • bilirubin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females
  • Age ≥18 and ≤75 years
  • Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct changes consistent with PSC
  • IBD diagnosed according to international guidelines (presence of endoscopic and histologic signs)
  • IBD inactive for at least 6 months (defined by no evidence of flare and no change in treatment)
  • ALP ≥ 1.3 (at least 2 times within a 3 months pre-inclusion period) or elevated total ≤50 umol/l (with concomitant elevated direct bilirubin).
  • Treatment with UDCA (13-23 mg/kg/d) for at least 6 months and at the same dosage for at least 3 months
  • Using in women of and agrees to pursue it from inclusion until week 48. Women of childbearing potential, i.e. fertile, following menarche and until becoming post-menopaused unless permanently sterile, who are sexually active have to apply a highly effective method of birth control with a low failure rate (i.e. less than 1% per year) when used constantly and correctly.
  • Written signed
  • Subject affiliated to the French
  • Social Security System

Exclusion criteria

Exclusion Criteria:

  • Small duct PSC
  • hepatitis defined by the presence of moderate to severe interface hepatitis documented on liver and at least 1 of the 2 following criteria: or ALT > 5 , Positive anti smooth muscle auto antibodies or serum IgG > 1.5 ULN
  • Secondary sclerosing cholangitis (notably IgG4-associated cholangitis)
  • Cirrhosis defined by Liver elastometry >14.4 kPa or by current or past decompensation of cirrhosis
  • AST or ALT > 7 ULN in the last 3 months
  • count in the last 3 months \< 100 000/mm3
  • Albumin in the last 3 months \<35g/L
  • Prothrombin index in the last 3 months \< 70%
  • Hepatic comorbidity: infection (defined by positive Ag HBS), infection (defined by positive HCV RNA), alcohol abuse (defined by alcohol intake > 30g/day), metabolic dysfunction associated steatohepatitis, primary biliary cholangitis, Hemochromatosis, Wilson disease, α1-antitrypsin deficiency, celiac disease
  • History of acute cholangitis in the last 3 months prior to inclusion or current acute cholangitis
  • infection
  • Prior liver transplantation
  • Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned within 3 months post randomization date
  • History of or established or suspected hepatobiliary carcinoma.
  • Any severe comorbidity that may reduce
  • History of diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to inclusion)
  • Dosage changes of treatment for liver disease in the last 3 months or new treatment for liver disease started in the last 3 months
  • History of colorectal carcinoma or high-grade dypsplasia in previous screening colonoscopy
  • History of total colectomy
  • Current active IBD defined by a partial Mayo score > 2 in patients with ulcerative colitis (UC), unclassed colitis or a Crohn's Disease Activity Index (CDAI) > 150 in patients with Crohn's disease
  • Changes in IBD treatment or initiation of a new treatment for IBD in the last 3 months
  • Current treatment with biologics (anti-TNF agent, vedolizumab, ustekinumab) or JAK inhibitors (tofacitinnib) or prednisone > 10 mg/day or budesonide > 3 mg /day) (or treatment initiated less than one month)
  • Any to swallow capsules
  • Renal insufficiency (clearance\<60 ml/min)
  • Unable to consent, subject to legal or administrative decision (protection measure or deprivation of liberty) or involuntary psychiatric care.
  • Participation in another interventional research without prior consultation with the investigator responsible for the patient's monitoring in the present study (participation in other non-interventional studies is permitted)
  • Pregnancy or desire for pregnancy or breastfeeding

Randomization criteria

  • No pregnancy (or desire for in the next year)
  • No other hepatic pathology: HBV (positive HBs Ag), HCV (positive HCV antibody and positive PCR), autoimmune hepatitis
  • No HIV infection (positive serology HIV1+2 antibodies)
  • No documented Clostridium difficile infection at inclusion or \< 10 days preceding randomization (in case of infection discovered at inclusion)
  • No treatment with antibiotics, antifungics or probiotics \< 4 weeks.
  • Available FMT with EBV and CMV compatibility
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Fecal microbiota

    FMT with stools from healthy donors 3 sessions of FMT in addition to standard UDCA therapy. First session of FMT: during a colonoscopy. Second and third session of FMT: 20 FMT capsules at week 12 and 24

    Drug: Fecal microbiota transplantation (FMT)

  • Sham comparator
    Sham transplantation

    3 sessions of sham transplantation in addition to standard UDCA therapy. First session of sham transplantation: during a colonoscopy Second and third session of sham transplantation: 20 placebo capsules at week 12 and 24.

    Drug: Sham-transplantation (placebo)

Interventions

  • DrugFecal microbiota transplantation (FMT)

    One to 4 weeks after randomization, the patient will be hospitalized in one of the hepato-gastroenterology department involved in the study for the colonoscopy. The patient will then receive either FMT (suspension of 50g of stools in 300ml of cryopreservative solution) in the terminal ileum or the caecum. At W12 and W24 after first colonoscopy , the patient will receive orally 20 FMT (capsules swallowed in front of a physician or a nurse in hospital)

  • DrugSham-transplantation (placebo)

    One to 4 weeks after randomization, the patient will be hospitalized in one of the hepato-gastroenterology department involved in the study for the colonoscopy. The patient will then receive sham transplantation (FMT vehicle, i.e. 300ml of cryopreservative solution) in the terminal ileum or the caecum. At W12 and W24 after first colonoscopy , the patient will receive orally 20 sham capsules (capsules swallowed in front of a physician or a nurse in hospital)

06

What researchers measure

Primary outcomes

  1. To assess in patients with PSC the efficacy of FMT versus sham transplantation on ALP and bilirubin at week 48 addition to standard UDCA therapy.

    Proportion of success at week 48. Success is defined as patients with serum ALP \<1.3 ULN at week 48 and a reduction of, at least 15%, compared to baseline ALP level AND normal total bilirubin ≤ 1 ULN at week 48

    Time frame: at week 48

Secondary outcomes

  1. Efficacy of FMT on reduction of ALP and normalization of bilirubin level at week 12, 24, 36 and 48 individually

    Proportion of success at week 12, 24 , 36 and 48. Success is defined as patients with serum ALP \<1.3 ULN and a reduction of, at least 15%, compared to baseline ALP level AND normal total bilirubin ≤ 1 ULN

    Time frame: at week 12, 24, 36 and 48

  2. Efficacy of FMT on biochemical liver tests at week 12, 24, 36 and 48 (ALP, GGT, AST, ALT and bilirubin)

    Proportion of patients that normalized all liver tests (ALP \<1ULN and GGT \<1 ULN and AST \<1 ULN and ALT \<1 ULN and total bilirubin \<1 ULN) at week 12 24 36 and 48

    Time frame: at week 12, 24, 36 and 48

  3. Efficacy of FMT on liver fibrosis progression

    assessed by transient elastography at week 48 versus week 0

    Time frame: at week 48

  4. PSC prognostic scores

    PSC Prognostic scores including the MELD score, the Revised PSC Mayo Risk Score, the Amsterdam-Oxford prognostic model (week 0, week 48)

    Time frame: at week 0, 24 and 48

  5. Occurrence of liver events during the study period

    Percentage of patients with clinical or biological adverse events

    Time frame: between randomization and week 104

  6. Occurrence of liver events during the study period

    Survival rate without liver events

    Time frame: at week 48

07

Study locations

1 site
  • Hepatology Department, Saint Antoine Hospital
    Paris, 75012, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Apr 2029, 35 months later.

Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartEst.
May 2026
Primary completionEst.
Apr 2029
CompletionEst.
May 2030
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07477782
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
May 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
May 2030 (estimated)
Last update
Mar 17, 2026

Study contacts

Sara LEMOINNE, MD, PhD, PU-PH
Contact
sara.lemoinne@aphp.fr
+33 1 49 28 28 36 ext. +33
Sara LEMOINNE, MD, PhD, PU-PH
principal investigator · APHP

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion